Gilead has poached a senior player from Bristol-Myers Squibb (BMS) to serve as the Senior Vice President of its Research Biology division.
In his previous role, Dr Quigley served as Vice President and Head of BMS’ Tumour Microenvironment Modulation Thematic Research Centre and Site Head of the Redwood City, California location.
In that role, he was responsible for setting strategy for BMS’ oncology discovery portfolio and business development activities, overseeing target identification, validation and preclinical development of large and small molecule therapies.
Gilead has also promoted Dr Linda Higgins as Senior Vice President and Head of External Innovation.
She joined Gilead in 2010, leading a significant expansion of the company’s Biology organisation that included the establishment of Biologics and Biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.
Under Dr Higgins’ leadership, the Biology organisation supported the discovery and development of eight marketed products and the advancement of more than 30 compounds into development.